Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress
Eikon Therapeutics presented updated TeLuRide-005 data for its TLR7/8 dual-agonist EIK1001 plus pembrolizumab and chemotherapy in first-line stage 4 NSCLC at the 2026 ESMO Congress. In the squamous cohort, ORR was 72.4% with a 100% disease control rate and a 12.9-month median duration of response; pooled efficacy-evaluable data showed 63.1% ORR and 89.2% DCR. Tolerability was broadly similar to standard of care — 48.6% Grade 3+ TRAEs, 6.9% discontinuations, no treatment-related deaths — supporting outpatient systemic administration, a key differentiator versus prior TLR7/8 agents.
Key figures
- Drug Name
- EIK1001
- Phase Of Trial
- Phase 2 (TeLuRide-005); Phase 2/3 registrational (TeLuRide-008)
- Pooled dcr
- 89.2%
- Pooled orr
- 63.1%
- Dcr squamous
- 100%
- Orr squamous
- 72.4%
- Dcr non squamous
- 80.6%
- Orr non squamous
- 55.6%
- Trial participants
- 72
- Median dor squamous
- 12.9 months
- Grade3plus trae rate
- 48.6%
- Median dor non squamous
- 11.2 months
- Median followup squamous
- 12.7 months
- Trae discontinuation rate
- 6.9%
- Te Lu Ride 008 interim analysis
- 2H 2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.